ROCK inhibitors, such as fasudil, are in clinical trial for pulmonary hypertension and our studies suggest a potential beneficial effect of ROCK1 inhibitor for patients on dasatinib who develop peripheral edema, pleural pulmonary edema, and pulmonary hypertension. This evidence concerns the gene ROCK1 and pulmonary hypertension.